Share on StockTwits

Acceleron Pharma (NASDAQ:XLRN) CEO John L. Knopf sold 17,500 shares of Acceleron Pharma stock on the open market in a transaction dated Thursday, August 14th. The stock was sold at an average price of $29.78, for a total value of $521,150.00. Following the sale, the chief executive officer now directly owns 156,500 shares in the company, valued at approximately $4,660,570. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Acceleron Pharma (NASDAQ:XLRN) traded down 0.50% during mid-day trading on Friday, hitting $29.81. The stock had a trading volume of 140,234 shares. Acceleron Pharma has a 52-week low of $16.78 and a 52-week high of $57.89. The stock has a 50-day moving average of $29.63 and a 200-day moving average of $35.97. The company’s market cap is $947.9 million.

Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Tuesday, August 12th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.01. On average, analysts predict that Acceleron Pharma will post $-1.44 earnings per share for the current fiscal year.

A number of research firms have recently commented on XLRN. Analysts at Leerink Swann initiated coverage on shares of Acceleron Pharma in a research note on Thursday. They set an “outperform” rating and a $57.00 price target on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Acceleron Pharma in a research note on Wednesday. They set an “outperform” rating and a $47.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating, Acceleron Pharma currently has a consensus rating of “Buy” and a consensus price target of $51.00.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.